Search Results for "Belsomra"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Belsomra. Results 1 to 4 of 4 total matches.
See also: Suvorexant
Lemborexant (Dayvigo) for Insomnia
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
.
It is the second orexin receptor antagonist to be
approved for this indication; suvorexant (Belsomra ...
The FDA has approved lemborexant (Dayvigo – Eisai),
an orexin receptor antagonist, for treatment of sleep-onset
and/or sleep-maintenance insomnia in adults. It
is the second orexin receptor antagonist to be approved
for this indication; suvorexant (Belsomra) was the first.
Daridorexant (Quviviq) for Insomnia
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022 (Issue 1654)
. Daridorexant is the third orexin receptor
antagonist to be approved for this indication;
suvorexant (Belsomra ...
The FDA has approved daridorexant (Quviviq –
Idorsia), an orexin receptor antagonist, for treatment
of sleep-onset and/or sleep-maintenance insomnia
in adults. Daridorexant is the third orexin receptor
antagonist to be approved for this indication;
suvorexant (Belsomra) and lemborexant (Dayvigo)
were approved earlier.
Drugs for Chronic Insomnia
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
ANTAGONISTS — Daridorexant
(Quviviq), lemborexant (Dayvigo), and suvorexant
(Belsomra) are FDA-approved ...
Cognitive behavioral therapy for insomnia (CBT-I) is
recommended for initial treatment of chronic insomnia.
CBT-I includes stimulus control, sleep education
and hygiene, sleep restriction, relaxation training, and
cognitive therapy. When CBT-I alone is not effective,
pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6 doi:10.58347/tml.2023.1667a | Show Introduction Hide Introduction
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
Dose1,2 Cost3 Some Adverse Effects Comments
Orexin Receptor Antagonists
Suvorexant – Belsomra
(Merck ...
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e6-10 doi:10.58347/tml.2023.1667b | Show Introduction Hide Introduction